Natera (NTRA) Competitors

Natera logo
$288.48 -30.61 (-9.59%)
Closing price 04:00 PM Eastern
Extended Trading
$294.00 +5.52 (+1.91%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NTRA vs. GILD, VRTX, MRNA, REGN, and ARGX

Should you buy Natera stock or one of its competitors? Natera's main competitors and comparable companies include Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Moderna (MRNA), Regeneron Pharmaceuticals (REGN), and argenex (ARGX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Natera compare to Gilead Sciences?

Natera (NASDAQ:NTRA) and Gilead Sciences (NASDAQ:GILD) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Gilead Sciences has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Natera$2.31B20.06-$208.16M-$1.14N/A
Gilead Sciences$29.44B7.08$8.51B-$3.16N/A

Natera currently has a consensus price target of $394.31, indicating a potential upside of 23.57%. Gilead Sciences has a consensus price target of $171.07, indicating a potential upside of 1.78%. Given Natera's stronger consensus rating and higher possible upside, analysts clearly believe Natera is more favorable than Gilead Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Natera
2 Sell rating(s)
2 Hold rating(s)
17 Buy rating(s)
2 Strong Buy rating(s)
2.83
Gilead Sciences
0 Sell rating(s)
6 Hold rating(s)
23 Buy rating(s)
0 Strong Buy rating(s)
2.79

In the previous week, Gilead Sciences had 31 more articles in the media than Natera. MarketBeat recorded 47 mentions for Gilead Sciences and 16 mentions for Natera. Gilead Sciences' average media sentiment score of 1.00 beat Natera's score of 0.43 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Natera
4 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Gilead Sciences
23 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

99.9% of Natera shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 5.1% of Natera shares are owned by insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Natera has a net margin of -5.66% compared to Gilead Sciences' net margin of -12.47%. Gilead Sciences' return on equity of -1.85% beat Natera's return on equity.

Company Net Margins Return on Equity Return on Assets
Natera-5.66% -8.61% -5.93%
Gilead Sciences -12.47%-1.85%-0.61%

Natera has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

Summary

Natera beats Gilead Sciences on 9 of the 17 factors compared between the two stocks.

How does Natera compare to Vertex Pharmaceuticals?

Natera (NASDAQ:NTRA) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Vertex Pharmaceuticals has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Natera$2.31B20.06-$208.16M-$1.14N/A
Vertex Pharmaceuticals$12.95B10.54$3.95B$15.5434.66

Vertex Pharmaceuticals has a net margin of 30.70% compared to Natera's net margin of -5.66%. Vertex Pharmaceuticals' return on equity of 21.98% beat Natera's return on equity.

Company Net Margins Return on Equity Return on Assets
Natera-5.66% -8.61% -5.93%
Vertex Pharmaceuticals 30.70%21.98%15.50%

99.9% of Natera shares are held by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. 5.1% of Natera shares are held by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Natera has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market.

In the previous week, Natera had 4 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 16 mentions for Natera and 12 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.89 beat Natera's score of 0.43 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Natera
4 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Vertex Pharmaceuticals
8 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Natera currently has a consensus target price of $394.31, indicating a potential upside of 23.57%. Vertex Pharmaceuticals has a consensus target price of $596.44, indicating a potential upside of 10.74%. Given Natera's higher probable upside, equities research analysts clearly believe Natera is more favorable than Vertex Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Natera
2 Sell rating(s)
2 Hold rating(s)
17 Buy rating(s)
2 Strong Buy rating(s)
2.83
Vertex Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
25 Buy rating(s)
1 Strong Buy rating(s)
2.96

Summary

Vertex Pharmaceuticals beats Natera on 10 of the 17 factors compared between the two stocks.

How does Natera compare to Moderna?

Natera (NASDAQ:NTRA) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Natera currently has a consensus price target of $394.31, indicating a potential upside of 23.57%. Moderna has a consensus price target of $113.75, indicating a potential downside of 49.08%. Given Natera's stronger consensus rating and higher probable upside, equities research analysts clearly believe Natera is more favorable than Moderna.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Natera
2 Sell rating(s)
2 Hold rating(s)
17 Buy rating(s)
2 Strong Buy rating(s)
2.83
Moderna
4 Sell rating(s)
15 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.08

99.9% of Natera shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 5.1% of Natera shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Natera has a net margin of -5.66% compared to Moderna's net margin of -110.46%. Natera's return on equity of -8.61% beat Moderna's return on equity.

Company Net Margins Return on Equity Return on Assets
Natera-5.66% -8.61% -5.93%
Moderna -110.46%-25.79%-15.85%

Natera has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, Moderna has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

Natera has higher earnings, but lower revenue than Moderna. Natera is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Natera$2.31B20.06-$208.16M-$1.14N/A
Moderna$2.52B35.87-$2.82B-$7.10N/A

In the previous week, Moderna had 41 more articles in the media than Natera. MarketBeat recorded 57 mentions for Moderna and 16 mentions for Natera. Moderna's average media sentiment score of 0.49 beat Natera's score of 0.43 indicating that Moderna is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Natera
4 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Moderna
16 Very Positive mention(s)
14 Positive mention(s)
12 Neutral mention(s)
4 Negative mention(s)
3 Very Negative mention(s)
Neutral

Summary

Natera beats Moderna on 11 of the 17 factors compared between the two stocks.

How does Natera compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

Regeneron Pharmaceuticals has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market. Comparatively, Natera has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market.

Regeneron Pharmaceuticals has a net margin of 28.51% compared to Natera's net margin of -5.66%. Regeneron Pharmaceuticals' return on equity of 16.01% beat Natera's return on equity.

Company Net Margins Return on Equity Return on Assets
Regeneron Pharmaceuticals28.51% 16.01% 12.22%
Natera -5.66%-8.61%-5.93%

Regeneron Pharmaceuticals has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$14.34B6.89$4.50B$45.2921.10
Natera$2.31B20.06-$208.16M-$1.14N/A

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 5.1% of Natera shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Regeneron Pharmaceuticals had 3 more articles in the media than Natera. MarketBeat recorded 19 mentions for Regeneron Pharmaceuticals and 16 mentions for Natera. Regeneron Pharmaceuticals' average media sentiment score of 0.62 beat Natera's score of 0.43 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Regeneron Pharmaceuticals
6 Very Positive mention(s)
4 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Natera
4 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Regeneron Pharmaceuticals currently has a consensus target price of $898.97, suggesting a potential downside of 5.91%. Natera has a consensus target price of $394.31, suggesting a potential upside of 23.57%. Given Natera's stronger consensus rating and higher possible upside, analysts plainly believe Natera is more favorable than Regeneron Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Regeneron Pharmaceuticals
0 Sell rating(s)
9 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.74
Natera
2 Sell rating(s)
2 Hold rating(s)
17 Buy rating(s)
2 Strong Buy rating(s)
2.83

Summary

Regeneron Pharmaceuticals beats Natera on 11 of the 17 factors compared between the two stocks.

How does Natera compare to argenex?

Natera (NASDAQ:NTRA) and argenex (NASDAQ:ARGX) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Natera has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market. Comparatively, argenex has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market.

argenex has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Natera$2.31B20.06-$208.16M-$1.14N/A
argenex$4.25B14.21$1.29B$28.6633.50

In the previous week, argenex had 1 more articles in the media than Natera. MarketBeat recorded 17 mentions for argenex and 16 mentions for Natera. argenex's average media sentiment score of 0.52 beat Natera's score of 0.43 indicating that argenex is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Natera
4 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
argenex
6 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Natera currently has a consensus price target of $394.31, indicating a potential upside of 23.57%. argenex has a consensus price target of $1,155.24, indicating a potential upside of 20.33%. Given Natera's stronger consensus rating and higher possible upside, equities research analysts plainly believe Natera is more favorable than argenex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Natera
2 Sell rating(s)
2 Hold rating(s)
17 Buy rating(s)
2 Strong Buy rating(s)
2.83
argenex
0 Sell rating(s)
6 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.82

99.9% of Natera shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 5.1% of Natera shares are owned by company insiders. Comparatively, 2.4% of argenex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

argenex has a net margin of 31.66% compared to Natera's net margin of -5.66%. argenex's return on equity of 47.70% beat Natera's return on equity.

Company Net Margins Return on Equity Return on Assets
Natera-5.66% -8.61% -5.93%
argenex 31.66%47.70%40.12%

Summary

argenex beats Natera on 10 of the 17 factors compared between the two stocks.

Get Natera News Delivered to You Automatically

Sign up to receive the latest news and ratings for NTRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NTRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NTRA vs. The Competition

MetricNateraBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$46.83B$4.15B$7.85B$12.17B
Dividend YieldN/A3.62%2.46%4.41%
P/E RatioN/A26.5532.9127.37
Price / Sales18.1416.058.595.73
Price / CashN/A26.3721.9322.50
Price / Book22.384.074.403.70
Net Income-$208.16M-$22.86M$3.52B$392.17M
7 Day Performance-9.96%-7.26%-5.34%-4.53%
1 Month Performance-26.68%-4.96%-3.61%-5.86%
1 Year Performance41.22%-2.87%0.01%-7.78%

Natera Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NTRA
Natera
3.4066 of 5 stars
$288.48
-9.6%
$394.31
+36.7%
+56.2%$46.83B$2.31BN/A6,140
GILD
Gilead Sciences
3.2598 of 5 stars
$169.32
+1.5%
$170.15
+0.5%
+34.4%$207.00B$30.99BN/A17,000
VRTX
Vertex Pharmaceuticals
3.3232 of 5 stars
$550.87
+0.7%
$596.44
+8.3%
+23.2%$139.20B$12.00B32.286,400
MRNA
Moderna
1.4194 of 5 stars
$269.00
+5.8%
$113.75
-57.7%
+801.8%$103.15B$1.94BN/A4,700
REGN
Regeneron Pharmaceuticals
3.7036 of 5 stars
$919.96
+1.7%
$898.97
-2.3%
+37.8%$95.82B$14.34B19.4915,410

Related Companies and Tools


This page (NASDAQ:NTRA) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners